The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID) (NIH)

Overall Status

Terminated

CT.gov ID

NCT00000961

Collaborator

Abbott (Industry), Glaxo Wellcome (Industry)

112

Enrollment

Study Details

Study Description

Brief Summary

To determine the safety and tolerance of hyperimmune anti-HIV intravenous immunoglobulin (HIVIG) and of zidovudine (AZT) in infants with established HIV infection; to get preliminary evidence for the effectiveness of this type of treatment in preventing the advance of disease in HIV infected infants. HIVIG may be an effective agent that either alone or in combination with AZT will prevent progression of clinical disease.

Condition or Disease	Intervention/Treatment	Phase
HIV Infections	Drug: Anti-HIV Immune Serum Globulin (Human) Drug: Zidovudine	Phase 2

Detailed Description

HIVIG may be an effective agent that either alone or in combination with AZT will prevent progression of clinical disease.

Participants are randomized to receive either oral AZT or HIVIG. Patients may receive treatment for a maximum of 48 weeks. Patients are evaluated during treatment at weeks 2, 4, and every 4 weeks thereafter. Infants who are receiving HIVIG initially are treated with the appropriate age-adjusted dose of oral AZT in addition to HIVIG if they meet clinical disease progression criteria. All participants who have completed 48 weeks of treatment or who are discontinued from treatment are followed every 3 months for an additional 48 weeks. This follow-up may be conducted over the telephone.

Study Design

Study Type:

Interventional

Intervention Model:

Parallel Assignment

Primary Purpose:

Treatment

Official Title:

A Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HIVIG) and of Zidovudine (ZDV) in Infants With Documented HIV Infections

Actual Primary Completion Date :

May 1, 1991

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

1 Day to 3 Months

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria

Concurrent Medication:

Allowed:

Recommended:
Standard immunizations. Should repeat MMR 3 months after discontinuing study.
Benadryl and/or aspirin.
Pneumocystis carinii pneumonia prophylaxis.
Systemic ketoconazole and acyclovir, or oral nystatin for acute therapy.
Aerosol ribavirin for short-term treatment of RSV.

Concurrent Treatment:

Allowed:

Blood transfusion.

Patients must have the following:

Parent or guardian available to give written informed consent.
Protocol requires prior Institutional Review Board (IRB) approval before any subject is entered into study.

Prior Medication:

Allowed:

Gammaglobulin, intravenous (IV) or intramuscular (IM).
Immunoglobulin, IV (IVIG).
Maternal antiretroviral treatment during pregnancy.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry.
Presence of serious acute infection requiring parenteral treatment at time of study entry.

Concurrent Medication:

Excluded:

Prophylaxis for oral candidiasis or otitis media or other infections.
Immunoglobulin therapy (except single dose or for hypogammaglobulinemia).
Ketoconazole, acyclovir, or nystatin for prophylaxis.

Patients with the following are excluded:

Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry.
Presence of serious acute infection requiring parenteral treatment at time of study entry.